Can a new pill help a failing heart pump better?

NCT ID NCT07750873

Recruiting now Disease control Sponsor: Cardurion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This clinical trial is testing an experimental drug called CRD-4730 in people with heart failure with reduced ejection fraction (HFrEF), a condition where the heart's main pumping chamber is weak. The drug works by blocking a protein called CaMKII, which is thought to contribute to heart muscle damage. The study will compare three different doses of CRD-4730 against a placebo, given alongside standard heart failure medications, to see if it can improve heart function and reduce strain on the heart over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CRD-4730, an experimental drug that inhibits CaMKII, a protein involved in heart cell stress and dysfunction
What this could lead to: If successful, this could lead to a new treatment option for heart failure with reduced ejection fraction, potentially improving heart function and reducing symptoms.
What could go wrong: This is a phase 2 trial, so results are preliminary and may not translate to real-world benefit. The drug may cause side effects or fail to show significant improvement over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cardurion Investigative Site
RECRUITING

Pasadena, California, 91105, United States
Cardurion Investigative Site
RECRUITING

Bloomfield Hills, Michigan, 48304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.